Home » Newsletters » BioWorld

BioWorld

Jan. 30, 1991

View Archived Issues

GENICA COMPLETES THIRD ROUND OF FINANCING

COURT DISMISSES MEDCO SHAREHOLDER SUIT

CARRINGTON SAYS EX-PRESIDENT CLEARED

EARNINGS REPORTS

JACOBS NAMED SYSTEMIX CHAIRMAN

ALTERED CELLS USED IN CANCER THERAPY

FDA GRANTS DNase ORPHAN STATUS

BIOLOGICAL DEFENSE SPENDING CHALLENGED

FDA RULE WOULD HINDER 'ME-TOO' ORPHAN DRUGS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...